Physicians' Academy for Cardiovascular Education

New diabetes drugs and heart failure: What have we learnt?

May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure 2017

Video navigation menu

  • History of CV outcome trials in type 2 diabetes 01:20
  • Effect of incretin-based therapies on heart failure 05:24
  • Major CV outcomes trials with DPP4-inhibitors  06:10
  • Major CV outcomes trials with GLP-1 receptor agonists 11:17
  • Effect of GLP-1 receptor agonists on HF hospitalization 14:35
  • SGLT2-inhibitors: ho do they reduce CV risk? 16:41

Educational information

This lecture was part of a CME accredited symposium: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach held at Heart Failure 2017 in Paris.

Educational objectives:

Disclosures

Professor John McMurray is a Professor of Medical Cardiology at the University of Glasgow and Honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.

Funding

This EBAC accredited symposium was funded by an unrestricted educational grant received from Boehringer-Ingelheim/Lilly

View slides of this lecture